fenofibrate has been researched along with Chronic Kidney Failure in 15 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report on a 26-year-old male who presented with fenofibrate-induced rhabdomyolysis with chronic renal failure due to nephrotic syndrome." | 7.78 | Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, FM; Erkoc, R; Soyoral, YU, 2012) |
| "Fenofibrate is a fibric acid derivative agent that is used in the treatment of hyperlipidaemia." | 5.38 | Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, MF; Erkoc, R; Soyoral, YU, 2012) |
| "In people with type 2 diabetes at high risk for cardiovascular disease, intensive glycemic control may result in a long-term reduction in macroalbuminuria; however, intensive BP control and fenofibrates may increase the risk for adverse kidney events." | 5.27 | Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. ( Buse, JB; Craven, TE; Ismail-Beigi, F; Katz, L; Mottl, AK; Mychaleckyj, JC; Papademetriou, V; Pedley, CF; Sigal, RJ; Simmons, DL, 2018) |
| "Fenofibrate is a potent hypolipemic agent, widely used in patients with mild to severe renal failure in whom hyperlipoproteinemia is frequent." | 5.09 | [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. ( Achard, JM; el Esper, N; Fournier, A; Hottelart, C; Pruna, A, 1999) |
| "We report on a 26-year-old male who presented with fenofibrate-induced rhabdomyolysis with chronic renal failure due to nephrotic syndrome." | 3.78 | Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, FM; Erkoc, R; Soyoral, YU, 2012) |
| "Fenofibrate treatment should not be contraindicated in moderate renal impairment, suggesting that current guidelines may be too restrictive." | 2.77 | Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. ( Celermajer, D; Davis, TM; Donoghoe, MW; Drury, PL; Hedley, J; Jenkins, AJ; Keech, AC; Lehto, S; Rajamani, K; Simes, RJ; Stanton, K; Ting, RD, 2012) |
| "Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease." | 2.44 | Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. ( Brown, WV, 2008) |
| "Fenofibrate is a fibric acid derivative agent that is used in the treatment of hyperlipidaemia." | 1.38 | Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, MF; Erkoc, R; Soyoral, YU, 2012) |
| " Several studies have found that long-term use of LLDs is associated with an increased risk of gallstone disease (GSD) in the general population." | 1.37 | Long-term use of fenofibrate is associated with increased prevalence of gallstone disease among patients undergoing maintenance hemodialysis. ( Chang, CT; Hsu, WM; Huang, CC; Kuo, HL; Liang, CC; Lin, HH; Liu, YL; Wang, IK; Yeh, HC, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yen, CL | 1 |
| Fan, PC | 1 |
| Lin, MS | 1 |
| Lee, CC | 1 |
| Tu, KH | 1 |
| Chen, CY | 1 |
| Hsiao, CC | 1 |
| Hsu, HH | 1 |
| Tian, YC | 1 |
| Chang, CH | 1 |
| Streja, E | 1 |
| Streja, DA | 1 |
| Soohoo, M | 1 |
| Kleine, CE | 1 |
| Hsiung, JT | 1 |
| Park, C | 1 |
| Moradi, H | 1 |
| Mottl, AK | 1 |
| Buse, JB | 1 |
| Ismail-Beigi, F | 1 |
| Sigal, RJ | 1 |
| Pedley, CF | 1 |
| Papademetriou, V | 1 |
| Simmons, DL | 1 |
| Katz, L | 1 |
| Mychaleckyj, JC | 1 |
| Craven, TE | 1 |
| Soyoral, YU | 2 |
| Canbaz, ET | 2 |
| Erdur, MF | 1 |
| Emre, H | 2 |
| Begenik, H | 2 |
| Erkoc, R | 2 |
| Hu, Z | 1 |
| Huang, S | 1 |
| Wu, Y | 1 |
| Liu, Y | 1 |
| Liu, X | 1 |
| Su, D | 1 |
| Tao, Y | 1 |
| Fu, P | 1 |
| Zhang, X | 1 |
| Peng, Z | 1 |
| Zhang, S | 1 |
| Yang, Y | 1 |
| Brown, WV | 1 |
| Liang, CC | 1 |
| Wang, IK | 1 |
| Kuo, HL | 1 |
| Yeh, HC | 1 |
| Lin, HH | 1 |
| Liu, YL | 1 |
| Hsu, WM | 1 |
| Huang, CC | 1 |
| Chang, CT | 1 |
| Erdur, FM | 1 |
| Ting, RD | 1 |
| Keech, AC | 1 |
| Drury, PL | 1 |
| Donoghoe, MW | 1 |
| Hedley, J | 1 |
| Jenkins, AJ | 1 |
| Davis, TM | 1 |
| Lehto, S | 1 |
| Celermajer, D | 1 |
| Simes, RJ | 1 |
| Rajamani, K | 1 |
| Stanton, K | 1 |
| Meas, T | 1 |
| Cimadevilla, C | 1 |
| Timsit, J | 1 |
| Mouly, S | 1 |
| Guillausseau, PJ | 1 |
| Desager, JP | 1 |
| Costermans, J | 1 |
| Verberckmoes, R | 1 |
| Harvengt, C | 1 |
| Hottelart, C | 1 |
| el Esper, N | 1 |
| Achard, JM | 1 |
| Pruna, A | 1 |
| Fournier, A | 1 |
| Landray, MJ | 1 |
| Townend, JN | 1 |
| Martin, S | 1 |
| Martin, U | 1 |
| Wheeler, DC | 1 |
| Levin, A | 1 |
| Duncan, L | 1 |
| Djurdjev, O | 1 |
| Shapiro, RJ | 1 |
| Frohlich, J | 1 |
| Belanger, A | 1 |
| Dumas, R | 1 |
| Ross, S | 1 |
| Chapman, MJ | 1 |
3 reviews available for fenofibrate and Chronic Kidney Failure
| Article | Year |
|---|---|
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hy | 2018 |
Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dys | 2008 |
Pharmacology of fenofibrate.
Topics: Biological Transport; Fenofibrate; Food; Half-Life; Humans; Intestinal Absorption; Kidney; Kidney Fa | 1987 |
4 trials available for fenofibrate and Chronic Kidney Failure
| Article | Year |
|---|---|
Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Ty | 2018 |
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glomerular Filtration | 2012 |
[Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].
Topics: Aged; Creatinine; Cross-Over Studies; Female; Fenofibrate; Glomerular Filtration Rate; Humans; Hyper | 1999 |
A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate.
Topics: Adult; Aged; Combined Modality Therapy; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipid | 2000 |
8 other studies available for fenofibrate and Chronic Kidney Failure
| Article | Year |
|---|---|
Fenofibrate Delays the Need for Dialysis and Reduces Cardiovascular Risk Among Patients With Advanced CKD.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Disease Progression; Female; Fenofibrate; Hear | 2021 |
Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Fenofibrate; Humans; Hypolipidemic Agent | 2012 |
Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.
Topics: Adolescent; Adult; Aged; Apolipoprotein E2; Biomarkers; Biopsy; Case-Control Studies; China; Creatin | 2014 |
Long-term use of fenofibrate is associated with increased prevalence of gallstone disease among patients undergoing maintenance hemodialysis.
Topics: Aged; Cross-Sectional Studies; Female; Fenofibrate; Gallstones; Humans; Hypolipidemic Agents; Kidney | 2011 |
Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report.
Topics: Adult; Fatigue; Fenofibrate; Humans; Hypertension; Hypoalbuminemia; Hypolipidemic Agents; Kidney Fai | 2012 |
Elevation of CKP induced by ezetimibe in monotherapy: report on two cases.
Topics: Anticholesteremic Agents; Azetidines; Creatine Kinase; Creatinine; Diabetes Mellitus, Type 2; Ezetim | 2006 |
Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure.
Topics: Adult; Aged; Female; Fenofibrate; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; Prop | 1982 |
Lipid-lowering drugs and homocysteine.
Topics: Fenofibrate; Homocysteine; Humans; Hypolipidemic Agents; Kidney Failure, Chronic; Middle Aged | 1999 |